id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327109-2fh004df	Polyzos, Stergios A.	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)	2020-07-21		.txt	text/plain	3964	176	39	This special issue of "Metabolism, Clinical and Experimental" is dedicated to nonalcoholic fatty liver disease (NAFLD), a disease closely linked with the insulin resistance (IR) syndrome or metabolic syndrome (MetS) [1] and its related comorbidities, including obesity [2] , type 2 diabetes mellitus (T2DM) [3] , dyslipidemia [4] and cardiovascular disease [5] . While the compilation of this special issue was ongoing, two position articles on the nomenclature of the disease were published, proposing the change of the terminology from NAFLD to metabolic (dysfunction)-associated fatty liver disease (MAFLD) [28, 29] . Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease	./cache/cord-327109-2fh004df.txt	./txt/cord-327109-2fh004df.txt